Associated Papers
Lenalidomide promotes the development of TP53-mutated therapy-related myeloid neoplasms.
Sperling AS et al.
Blood, 2022
35512188 (PubMed )
Supplement: BLOOD_BLD-2021-014956-mmc1.pdf
Cellular stressors contribute to the expansion of hematopoietic clones of varying leukemic potential.
Wong TN et al.
Nature Communications, 2018
29386642 (PubMed )
Supplement: 41467_2018_2858_MOESM5_ESM.xlsx › Sheet1
Response to Targeted Therapy in BRAF Mutant Anaplastic Thyroid Cancer.
Agarwal R et al.
Journal of the National Comprehensive Cancer Network : Jnccn, 2016
Select a paper to view details